Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.5301 EUR
−14.94 M EUR
0.00 EUR
26.49 M
About FibroBiologics, Inc.
Sector
Industry
CEO
Peter O'Heeron
Website
Headquarters
Houston
Founded
2021
FIGI
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange FibroBiologics, Inc. stocks are traded under the ticker A3EP67.
A3EP67 stock hasn't changed in a week, the last month showed zero change in price, over the last year FibroBiologics, Inc. has showed a −4.02% decrease.
We've gathered analysts' opinions on FibroBiologics, Inc. future price: according to them, A3EP67 price has a max estimate of 15.20 EUR and a min estimate of 10.45 EUR. Watch A3EP67 chart and read a more detailed FibroBiologics, Inc. stock forecast: see what analysts think of FibroBiologics, Inc. and suggest that you do with its stocks.
A3EP67 stock is 4.19% volatile and has beta coefficient of 0.68. Track FibroBiologics, Inc. stock price on the chart and check out the list of the most volatile stocks — is FibroBiologics, Inc. there?
Yes, you can track FibroBiologics, Inc. financials in yearly and quarterly reports right on TradingView.
FibroBiologics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
A3EP67 earnings for the last quarter are −0.01 EUR per share, whereas the estimation was −0.06 EUR resulting in a 86.15% surprise. The estimated earnings for the next quarter are −0.09 EUR per share. See more details about FibroBiologics, Inc. earnings.
FibroBiologics, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
A3EP67 net income for the last quarter is −449.07 K EUR, while the quarter before that showed 838.37 K EUR of net income which accounts for −153.56% change. Track more FibroBiologics, Inc. financial stats to get the full picture.
No, A3EP67 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 10.00 employees. See our rating of the largest employees — is FibroBiologics, Inc. on this list?
Like other stocks, A3EP67 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FibroBiologics, Inc. stock right from TradingView charts — choose your broker and connect to your account.